Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Heart Failure Reviews
Published in: Heart Failure Reviews 1/2019

01-01-2019

Metabolic remodeling of substrate utilization during heart failure progression

Authors: Liang Chen, Jiangping Song, Shengshou Hu

Published in: Heart Failure Reviews | Issue 1/2019

Login to get access

Abstract

Heart failure (HF) is a clinical syndrome caused by a decline in cardiac systolic or diastolic function, which leaves the heart unable to pump enough blood to meet the normal physiological requirements of the human body. It is a serious disease burden worldwide affecting nearly 23 million patients. The concept that heart failure is “an engine out of fuel” has been generally accepted and metabolic remodeling has been recognized as an important aspect of this condition; it is characterized by defects in energy production and changes in metabolic pathways involved in the regulation of essential cellular functions such as the process of substrate utilization, the tricarboxylic acid cycle, oxidative phosphorylation, and high-energy phosphate metabolism. Advances in second-generation sequencing, proteomics, and metabolomics have made it possible to perform comprehensive tests on genes and metabolites that are crucial in the process of HF, thereby providing a clearer and comprehensive understanding of metabolic remodeling during HF. In recent years, new metabolic changes such as ketone bodies and branched-chain amino acids were demonstrated as alternative substrates in end-stage HF. This systematic review focuses on changes in metabolic substrate utilization during the progression of HF and the underlying regulatory mechanisms. Accordingly, the conventional concepts of metabolic remodeling characteristics are reviewed, and the latest developments, particularly multi-omics studies, are compiled.
Literature
1.
Shen L et al (2017) Declining risk of sudden death in heart failure. N Engl J Med 377(1):41–51PubMed
2.
Dunlay SM, Roger VL, Redfield MM (2017) Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol 14(10):591–602PubMed
3.
Velazquez EJ et al (2016) Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med 374(16):1511–1520PubMedPubMedCentral
4.
Filion KB et al (2016) A multicenter observational study of incretin-based drugs and heart failure. N Engl J Med 374(12):1145–1154PubMed
5.
Felker GM et al (2017) Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 318(8):713–720PubMedPubMedCentral
6.
Ho KK et al (1993) The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 22(4 Suppl A):6A–13APubMed
7.
Doenst T, Nguyen TD, Abel ED (2013) Cardiac metabolism in heart failure: implications beyond ATP production. Circ Res 113(6):709–724PubMedPubMedCentral
8.
Byrne NJ et al (2016) Normalization of cardiac substrate utilization and left ventricular hypertrophy precede functional recovery in heart failure regression. Cardiovasc Res 110(2):249–257PubMedPubMedCentral
9.
Neubauer S (2007) The failing heart—an engine out of fuel. N Engl J Med 356(11):1140–1151PubMed
10.
Stanley WC, Recchia FA, Lopaschuk GD (2005) Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 85(3):1093–1129PubMed
11.
Fillmore N, Lopaschuk GD (2013) Targeting mitochondrial oxidative metabolism as an approach to treat heart failure. Biochim Biophys Acta 1833(4):857–865PubMed
12.
Lopaschuk GD et al (2010) Myocardial fatty acid metabolism in health and disease. Physiol Rev 90(1):207–258PubMed
13.
Szablewski L (2017) Glucose transporters in healthy heart and in cardiac disease. Int J Cardiol 230(1):70–75PubMed
14.
15.
Vimercati C et al (2014) Beneficial effects of acute inhibition of the oxidative pentose phosphate pathway in the failing heart. Am J Physiol Heart Circ Physiol 306(5):H709–H717PubMedPubMedCentral
16.
17.
Carley AN, Lewandowski ED (2016) Triacylglycerol turnover in the failing heart. Biochim Biophys Acta 1861(10):1492–1499PubMed
18.
Jenei ZA et al (2011) Packing of transmembrane domain 2 of carnitine palmitoyltransferase-1A affects oligomerization and malonyl-CoA sensitivity of the mitochondrial outer membrane protein. FASEB J 25(12):4522–4530PubMed
19.
Abdurrachim D et al (2015) Good and bad consequences of altered fatty acid metabolism in heart failure: evidence from mouse models. Cardiovasc Res 106(2):194–205PubMed
20.
O’Neill HM et al (2014) AMPK phosphorylation of ACC2 is required for skeletal muscle fatty acid oxidation and insulin sensitivity in mice. Diabetologia 57(8):1693–1702PubMed
21.
Saha AK et al (2000) Activation of malonyl-CoA decarboxylase in rat skeletal muscle by contraction and the AMP-activated protein kinase activator 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside. J Biol Chem 275(32):24279–24283PubMed
22.
Barreto-Torres G et al (2015) The beneficial effects of AMP kinase activation against oxidative stress are associated with prevention of PPARalpha-cyclophilin D interaction in cardiomyocytes. Am J Physiol Heart Circ Physiol 308(7):H749–H758PubMedPubMedCentral
23.
Sung MM et al (2015) AMPK deficiency in cardiac muscle results in dilated cardiomyopathy in the absence of changes in energy metabolism. Cardiovasc Res 107(2):235–245PubMedPubMedCentral
24.
Ashrafian H, Frenneaux MP, Opie LH (2007) Metabolic mechanisms in heart failure. Circulation 116(4):434–448PubMed
25.
Abushouk AI et al (2017) Peroxisome proliferator-activated receptors as therapeutic targets for heart failure. Biomed Pharmacother 95(1):692–700PubMed
26.
Lam VH et al (2015) Activating PPARalpha prevents post-ischemic contractile dysfunction in hypertrophied neonatal hearts. Circ Res 117(1):41–51PubMed
27.
Smeets PJ et al (2008) Cardiac hypertrophy is enhanced in PPAR alpha−/− mice in response to chronic pressure overload. Cardiovasc Res 78(1):79–89PubMed
28.
Drosatos K et al (2016) Cardiac myocyte KLF5 regulates Ppara expression and cardiac function. Circ Res 118(2):241–253PubMed
29.
Palomer X et al (2016) PPARbeta/delta and lipid metabolism in the heart. Biochim Biophys Acta 1861(10):1569–1578PubMed
30.
Burkart EM et al (2007) Nuclear receptors PPARbeta/delta and PPARalpha direct distinct metabolic regulatory programs in the mouse heart. J Clin Invest 117(12):3930–3939PubMedPubMedCentral
31.
32.
Abo AO, Lopaschuk GD (2014) Role of CoA and acetyl-CoA in regulating cardiac fatty acid and glucose oxidation. Biochem Soc Trans 42(4):1043–1051
33.
Guo Z (2015) Pyruvate dehydrogenase, Randle cycle, and skeletal muscle insulin resistance. Proc Natl Acad Sci U S A 112(22):E2854PubMedPubMedCentral
34.
Gomez-Arroyo J et al (2013) Metabolic gene remodeling and mitochondrial dysfunction in failing right ventricular hypertrophy secondary to pulmonary arterial hypertension. Circ Heart Fail 6(1):136–144PubMed
35.
Christe ME, Rodgers RL (1994) Altered glucose and fatty acid oxidation in hearts of the spontaneously hypertensive rat. J Mol Cell Cardiol 26(10):1371–1375PubMed
36.
Massie BM et al (1995) Myocardial high-energy phosphate and substrate metabolism in swine with moderate left ventricular hypertrophy. Circulation 91(6):1814–1823PubMed
37.
Degens H et al (2006) Cardiac fatty acid metabolism is preserved in the compensated hypertrophic rat heart. Basic Res Cardiol 101(1):17–26PubMed
38.
Seymour AM et al (2015) In vivo assessment of cardiac metabolism and function in the abdominal aortic banding model of compensated cardiac hypertrophy. Cardiovasc Res 106(2):249–260PubMedPubMedCentral
39.
Kato T et al (2010) Analysis of metabolic remodeling in compensated left ventricular hypertrophy and heart failure. Circ Heart Fail 3(3):420–430PubMed
40.
O’Donnell JM et al (2008) The absence of endogenous lipid oxidation in early stage heart failure exposes limits in lipid storage and turnover. J Mol Cell Cardiol 44(2):315–322PubMed
41.
Lai L et al (2014) Energy metabolic reprogramming in the hypertrophied and early stage failing heart: a multisystems approach. Circ Heart Fail 7(6):1022–1031PubMedPubMedCentral
42.
Burke MA et al (2016) Molecular profiling of dilated cardiomyopathy that progresses to heart failure. JCI Insight 1(6):e86898PubMedPubMedCentral
43.
Lionetti V, Stanley WC, Recchia FA (2011) Modulating fatty acid oxidation in heart failure. Cardiovasc Res 90(2):202–209PubMedPubMedCentral
44.
Heggermont WA et al (2016) Metabolic support for the heart: complementary therapy for heart failure? Eur J Heart Fail 18(12):1420–1429PubMed
45.
Pereira RO et al (2014) GLUT1 deficiency in cardiomyocytes does not accelerate the transition from compensated hypertrophy to heart failure. J Mol Cell Cardiol 72(1):95–103PubMedPubMedCentral
46.
Yan J et al (2009) Increased glucose uptake and oxidation in mouse hearts prevent high fatty acid oxidation but cause cardiac dysfunction in diet-induced obesity. Circulation 119(21):2818–2828PubMedPubMedCentral
47.
Kundu BK et al (2015) Remodeling of glucose metabolism precedes pressure overload-induced left ventricular hypertrophy: review of a hypothesis. Cardiology 130(4):211–220PubMedPubMedCentral
48.
Bedi KJ et al (2016) Evidence for Intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure. Circulation 133(8):706–716PubMedPubMedCentral
49.
Peterzan MA et al (2017) Metabolic remodeling in hypertrophied and failing myocardium: a review. Am J Physiol Heart Circ Physiol 313(3):H597–H616PubMed
50.
El AZ et al (1992) Fatty acid oxidation and mechanical performance of volume-overloaded rat hearts. Am J Phys 262(4 Pt 2):H1068–H1074
51.
Pound KM et al (2009) Substrate-enzyme competition attenuates upregulated anaplerotic flux through malic enzyme in hypertrophied rat heart and restores triacylglyceride content: attenuating upregulated anaplerosis in hypertrophy. Circ Res 104(6):805–812PubMedPubMedCentral
52.
Lei B et al (2004) Paradoxical downregulation of the glucose oxidation pathway despite enhanced flux in severe heart failure. J Mol Cell Cardiol 36(4):567–576PubMed
53.
Sansbury BE et al (2014) Metabolomic analysis of pressure-overloaded and infarcted mouse hearts. Circ Heart Fail 7(4):634–642PubMedPubMedCentral
54.
Davila-Roman VG et al (2002) Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 40(2):271–277PubMed
55.
Zhabyeyev P et al (2013) Pressure-overload-induced heart failure induces a selective reduction in glucose oxidation at physiological afterload. Cardiovasc Res 97(4):676–685PubMed
56.
Amorim PA et al (2010) Myocardial infarction in rats causes partial impairment in insulin response associated with reduced fatty acid oxidation and mitochondrial gene expression. J Thorac Cardiovasc Surg 140(5):1160–1167PubMed
57.
Osorio JC et al (2002) Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-alpha in pacing-induced heart failure. Circulation 106(5):606–612PubMed
58.
Doenst T et al (2010) Decreased rates of substrate oxidation ex vivo predict the onset of heart failure and contractile dysfunction in rats with pressure overload. Cardiovasc Res 86(3):461–470PubMed
59.
Gupte AA et al (2014) Mechanical unloading promotes myocardial energy recovery in human heart failure. Circ Cardiovasc Genet 7(3):266–276PubMedPubMedCentral
60.
Tuunanen H, Ukkonen H, Knuuti J (2008) Myocardial fatty acid metabolism and cardiac performance in heart failure. Curr Cardiol Rep 10(2):142–148PubMed
61.
62.
63.
Sun H et al (2016) Catabolic defect of branched-chain amino acids promotes heart failure. Circulation 133(21):2038–2049PubMedPubMedCentral
64.
Foster DB et al (2016) Integrated omic analysis of a guinea pig model of heart failure and sudden cardiac death. J Proteome Res 15(9):3009–3028PubMedPubMedCentral
65.
Hunter WG et al (2016) Metabolomic profiling identifies novel circulating biomarkers of mitochondrial dysfunction differentially elevated in heart failure with preserved versus reduced ejection fraction: evidence for shared metabolic impairments in clinical heart failure. J Am Heart Assoc 5(8):e003190PubMedPubMedCentral
66.
Ruiz M et al (2017) Circulating acylcarnitine profile in human heart failure: a surrogate of fatty acid metabolic dysregulation in mitochondria and beyond. Am J Physiol Heart Circ Physiol 313(4):H768–H781PubMed
67.
Ahmad T et al (2016) Prognostic implications of long-chain acylcarnitines in heart failure and reversibility with mechanical circulatory support. J Am Coll Cardiol 67(3):291–299PubMedPubMedCentral
68.
Fragasso G et al (2006) A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol 48(5):992–998PubMed
69.
Fragasso G et al (2011) Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure. Heart 97(18):1495–1500PubMed
70.
Tuunanen H et al (2006) Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure. Circulation 114(20):2130–2137PubMed
71.
Salerno A et al (2015) Effects of short-term manipulation of serum FFA concentrations on left ventricular energy metabolism and function in patients with heart failure: no association with circulating bio-markers of inflammation. Acta Diabetol 52(4):753–761PubMed
72.
Martin MA et al (2000) Myocardial carnitine and carnitine palmitoyltransferase deficiencies in patients with severe heart failure. Biochim Biophys Acta 1502(3):330–336PubMed
73.
Fillmore N, Mori J, Lopaschuk GD (2014) Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy. Br J Pharmacol 171(8):2080–2090PubMedPubMedCentral
74.
Wang Y et al (2013) Integrated proteomic and metabolomic analysis reveals the NADH-mediated TCA cycle and energy metabolism disorders based on a new model of chronic progressive heart failure. Mol BioSyst 9(12):3135–3145PubMed
75.
Warren JS et al (2017) Metabolic reprogramming via PPARalpha signaling in cardiac hypertrophy and failure: from metabolomics to epigenetics. Am J Physiol Heart Circ Physiol 313(3):H584–H596PubMed
76.
Kaimoto S et al (2017) Activation of PPAR-alpha in the early stage of heart failure maintained myocardial function and energetics in pressure-overload heart failure. Am J Physiol Heart Circ Physiol 312(2):H305–H313PubMed
77.
Oka S et al (2015) Peroxisome proliferator activated receptor-alpha association with silent information regulator 1 suppresses cardiac fatty acid metabolism in the failing heart. Circ Heart Fail 8(6):1123–1132PubMedPubMedCentral
78.
Morgan EE et al (2006) Effects of chronic activation of peroxisome proliferator-activated receptor-alpha or high-fat feeding in a rat infarct model of heart failure. Am J Physiol Heart Circ Physiol 290(5):H1899–H1904PubMed
79.
Ogata T et al (2004) Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway. J Am Coll Cardiol 43(8):1481–1488PubMed
80.
Brigadeau F et al (2007) The PPARalpha activator fenofibrate slows down the progression of the left ventricular dysfunction in porcine tachycardia-induced cardiomyopathy. J Cardiovasc Pharmacol 49(6):408–415PubMed
81.
Cheng L et al (2004) Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat Med 10(11):1245–1250PubMed
82.
El AH et al (2013) The hypoxia-inducible microRNA cluster miR-199a approximately 214 targets myocardial PPARdelta and impairs mitochondrial fatty acid oxidation. Cell Metab 18(3):341–354
83.
Sihag S et al (2009) PGC-1alpha and ERRalpha target gene downregulation is a signature of the failing human heart. J Mol Cell Cardiol 46(2):201–212PubMed
84.
Riehle C et al (2011) PGC-1beta deficiency accelerates the transition to heart failure in pressure overload hypertrophy. Circ Res 109(7):783–793PubMedPubMedCentral
85.
Lopaschuk GD, Ussher JR (2016) Evolving concepts of myocardial energy metabolism: more than just fats and carbohydrates. Circ Res 119(11):1173–1176PubMed
86.
87.
Cotter DG, Schugar RC, Crawford PA (2013) Ketone body metabolism and cardiovascular disease. Am J Physiol Heart Circ Physiol 304(8):H1060–H1076PubMedPubMedCentral
88.
Yokokawa T et al (2016) Exhaled acetone concentration is related to hemodynamic severity in patients with non-ischemic chronic heart failure. Circ J 80(5):1178–1186PubMed
89.
Obokata M et al (2017) Association between circulating ketone bodies and worse outcomes in hemodialysis patients. J Am Heart Assoc 6(10):e006885PubMedPubMedCentral
90.
Taegtmeyer H (2016) Failing heart and starving brain: ketone bodies to the rescue. Circulation 134(4):265–266PubMed
91.
Kolwicz SJ, Airhart S, Tian R (2016) Ketones step to the plate: a game changer for metabolic remodeling in heart failure? Circulation 133(8):689–691PubMedPubMedCentral
92.
Wang W et al (2016) Defective branched chain amino acid catabolism contributes to cardiac dysfunction and remodeling following myocardial infarction. Am J Physiol Heart Circ Physiol 311(5):H1160–H1169PubMed
93.
Tanada Y et al (2015) Branched-chain amino acids ameliorate heart failure with cardiac cachexia in rats. Life Sci 137(1):20–27PubMed
94.
Takata M et al (2017) An exploratory study on the efficacy and safety of a BCAA preparation used in combination with cardiac rehabilitation for patients with chronic heart failure. BMC Cardiovasc Disord 17(1):205PubMedPubMedCentral
95.
Huynh K (2016) Heart failure: ketone bodies as fuel in heart failure. Nat Rev Cardiol 13(3):122–123PubMed
96.
Biesele JJ, Tobioka M (1956) Mitochondria in living cells: an analysis of movements. J Biophys Biochem Cytol 2(4 Suppl):319–324PubMedPubMedCentral
97.
Maneechote C et al (2017) Roles of mitochondrial dynamics modulators in cardiac ischaemia/reperfusion injury. J Cell Mol Med 21(11):2643–2653PubMedPubMedCentral
98.
Nan J et al (2017) TNFR2 stimulation promotes mitochondrial fusion via Stat3- and NF-kB-dependent activation of OPA1 expression. Circ Res 121(4):392–410PubMedPubMedCentral
99.
Wai T et al (2015) Imbalanced OPA1 processing and mitochondrial fragmentation cause heart failure in mice. Science 350(6265):aad0116PubMed
100.
Nan J et al (2017) Molecular regulation of mitochondrial dynamics in cardiac disease. Biochim Biophys Acta 1864(7):1260–1273
101.
Martin OJ et al (2014) A role for peroxisome proliferator-activated receptor gamma coactivator-1 in the control of mitochondrial dynamics during postnatal cardiac growth. Circ Res 114(4):626–636PubMed
102.
Tsushima K et al (2018) Mitochondrial reactive oxygen species in Lipotoxic hearts induce post-translational modifications of AKAP121, DRP1, and OPA1 that promote mitochondrial fission. Circ Res 122(1):58–73PubMed
103.
104.
105.
Li Q et al (2015) Multiple mass isotopomer tracing of acetyl-CoA metabolism in Langendorff-perfused rat hearts: channeling of acetyl-CoA from pyruvate dehydrogenase to carnitine acetyltransferase. J Biol Chem 290(13):8121–8132PubMedPubMedCentral
106.
Nadtochiy SM et al (2015) Metabolomic profiling of the heart during acute ischemic preconditioning reveals a role for SIRT1 in rapid cardioprotective metabolic adaptation. J Mol Cell Cardiol 88(1):64–72PubMedPubMedCentral
Metadata
Title
Metabolic remodeling of substrate utilization during heart failure progression
Authors
Liang Chen
Jiangping Song
Shengshou Hu
Publication date
01-01-2019
Publisher
Springer US
Published in
Heart Failure Reviews / Issue 1/2019
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI
https://doi.org/10.1007/s10741-018-9713-0

Other articles of this Issue 1/2019

Heart Failure Reviews 1/2019 Go to the issue

ReviewPaper

Lanosteryl triterpenes from Protorhus longifolia as a cardioprotective agent: a mini review

ReviewPaper

Continuous versus intermittent administration of furosemide in acute decompensated heart failure: a systematic review and meta-analysis

ReviewPaper

Cardio-oncology: a new and developing sector of research and therapy in the field of cardiology

ReviewPaper

The effect of influenza vaccination on mortality and hospitalization in patients with heart failure: a systematic review and meta-analysis

ReviewPaper

Intercalated discs: cellular adhesion and signaling in heart health and diseases

ReviewPaper

Cell-based therapies for the treatment of myocardial infarction: lessons from cardiac regeneration and repair mechanisms in non-human vertebrates

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits